The new norm of e-conferencing continues IASLC #WCLC20. Our study showed that biopsy of a metastatic deposit was the most efficient and effective means of 'completely' diagnosing stage IV NSCLC, including for molecular and PDL1 testing. The Alfred

Australia and Asia Pacific Clinical Oncology Research Development (ACORD) one-week Protocol Workshop Applications now open. moga.org.au/acord-workshop

Our latest multi-centre study published in JAMA Oncology. Of almost 400 pts, 43% developed chronic irAEs after anti-PD1 therapy, mostly affecting nonvisceral organs. #notchemobutstilltoxic

Glad to see our work on delayed irAEs (onset >12 months after PD-1 initiation) published in Annals of Oncology, which can start over 2 years after stopping therapy, and be more difficult to manage.

Thankful for the support our #OvariesTalkAboutThem campaign with CAMILLA AND MARC has received over the last 48 hours. It’s incredibly motivating as we strive to develop an early detection test for #OvarianCancer to see this disease receiving more attention. Here’s why I care👇🏽

Our latest research for #melanoma brain mets in pts outside of clinical trials- Ipi/Nivo superior to BRAF/MEK & active even in dismal disease charact. Thanks to all collaborators for these important data ⁦Comprehensive Cancer Center Zurich⁩ ⁦Université de Lausanne⁩ ⁦Peter Mac Cancer Centre⁩ sciencedirect.com/science/articl…

Come and virtually see 👀 our poster exploring #immunotherapy 💉in Acral #melanoma, a rare but important subtype, at #ESMO21- with huge thanks to Matteo Carlino for supervising. ESMO - Eur. Oncology 🧬

Check out our latest publication in Journal for ImmunoTherapy of Cancer on 2nd line Ipi/Nivo 💉 after BRAF/MEK inhibitors 💊 in melanoma brain metastases 🧠 Peter Lau Peter Mac Cancer Centre

Our study in Journal for ImmunoTherapy of Cancer showing that #psoriasis 🩹should not be a major barrier to prescribing #immunotherapy 💉in #oncology patients 🧬🩸

Thank you COSA for the opportunity to present our work on #immunotherapy in #acralmelanoma. #COSA21 Matteo Carlino Melanoma Institute Australia @CPMCCWestmead

Typically thoughtful, perceptive, constructive, and self-deprecating: Nicholas Wilcken The Sydney Morning Herald. smh.com.au/national/the-h…

Awesome closing session to end the inspirational Peter Mac Cancer Centre Research Retreat. With bonus #PeterMac socks 🧦 🧬💉

Two years late thanks to covid, but better late than never 👩🏽‍🎓👩🏽‍⚕️The Royal Australasian College of Physicians

Wonderful morning of ‘fireside chats’ 🔥 at the Galli #research #colloquium, particularly seeing #researchers of diverse backgrounds (even astrophysicists 🪐) come together across institutions to advance #medical research 🧬💊Peter Mac Cancer Centre WEHI (Walter and Eliza Hall Institute) UniMelb MDHS

Check out 👀 our new paper 📜in Journal for ImmunoTherapy of Cancer on #immunotherapy 💉in #acral #melanoma, an important subtype with very limited #clinicaltrial data. 💊🩺 Peter Mac Research UniMelb Centre for Cancer Research Matteo Carlino Mark S UniMelb MDHS Grant McArthur

Thank you Melanoma MRV and the Mansell family for this generous award 🏆 Great motivation to keep going with #melanoma #research to find a #cure for this devastating disease 🩺

Happy to share our latest paper exploring the role of adjuvant #radiotherapy☢️in the modern era of #melanoma relapses on/after adjuvant #Immunotherapy 💉. Matteo Carlino Angela Hong Grant McArthur Melanoma Institute Australia Peter Mac Research

Our review on #melanoma management in Australia is now out in MJA! Check it out at doi.org/10.5694/mja2.5… (This paper will always hold a special place in my heart as I went into labour whilst reviewing the proofs 😅🤦🏽‍♀️) Dr Victoria Mar Peter Mac Cancer Centre The Alfred #WomenInSTEM

Our newest collaboration with Alex Menzies Adriana Hepner Matteo Carlino Dr. Jennifer McQuade Alex Shoushtari, MD etc. is online. Insights into acquired resistance to anti-PD-1 based therapy for melanoma. Further treatment with IO-based strategies led to best outcomes. authors.elsevier.com/c/1i7Pz3QE--VL…

The rate of endometrial cancer in Australia has almost doubled in two decades, with the survival rate alarmingly decreasing. But there is some fresh hope for women battling the disease, with a new treatment added to the Pharmaceutical Benefits Scheme | Chloe Bouras